Sens.ai

Future Processing

Sens.AI is a software solution designed to segment and calculate the volume of the biggest homogeneous pathological lesion, dedicated to low and high-grade gliomas (LGG and HGG) within the input MRI scan of human brain, by using T2-FLAIR 3D MRI sequence.

Product specifications

Information source: Vendor
Last updated: July 22, 2020

General
Product name	Sens.ai
Company	Future Processing
Subspeciality	Neuro
Modality	MR
Disease targeted	low and high grade glioblastoma
Key-features	lesion segmentation and volume calculation
Suggested use
Data characteristics
Population	all adults with glioblastoma
Input	FLAIR 3D MR sequence
Input format	DICOM
Output	lesion segmentation, volume calculation
Output format	DICOM
Technology
Integration	Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment	Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis	On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time	3 - 10 seconds
Certification
CE	Certified, Class IIa
FDA	No or not yet
Market presence
On market since	03-2020
Distribution channels	Eureka Clinical AI
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model
Based on
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers